

**FROM:**

**VÄSAMED**  
**7615 Golden Triangle Drive**  
**Minneapolis, MN 55344**  
**Contact: Wes Peterson, CFO**  
**(952) 944-5857 ext. 542**

**VÄSAMED ACQUIRES NON-INVASIVE CARDIAC OUTPUT TECHNOLOGY**

***Impedance Cardiography Technology 510(k) Cleared to Market***

MINNEAPOLIS, May 17 -- VÄSAMED (OTC Bulletin Board: OPTL) announced that it has acquired a proprietary Impedance Cardiography technology for non-invasive cardiac output (NICO) monitoring.

Paulita LaPlante, president and chief executive officer said, "In keeping with our mission to build a line of office-based diagnostic products that incorporate our wholly-owned intellectual property in blood flow and tissue perfusion, we are pleased to add NICO based on impedance cardiography (ICG). This product is one of very few FDA-cleared systems that measure ICG - the most notable competitor is Cardiodynamics. The firm from which we purchased this ICG technology is a private entity that spent time and resources developing proprietary algorithms and securing FDA clearance. Our next few months will be spent refining user interface software and modifying certain performance features and hardware before introducing a product to market. With this acquisition, we now control the principal components of the hemodynamic health platform we set out to create following the introduction of tissue carbon dioxide monitoring in 2000. Our vision of NICO is importantly different from other companies' products since we believe that we have unique ways to increase the integrity of the measurement thereby providing a reliable result to the customer."

VÄSAMED is a technology development company specializing in low-cost, non-invasive vascular diagnostic systems for non-invasive hemodynamic monitoring. Products developed by VÄSAMED include the *CapnoProbe*<sup>™</sup> sensor system for the measurement of sublingual CO<sub>2</sub>. OSI licensed an application of CapnoProbe technology to Nellcor in 2001 which has positioned the product as an early warning signal of tissue hypoperfusion and possible organ failure. VÄSAMED manufactures and supplies LASERDOPP PV2000, a skin perfusion pressure and pulse volume waveform diagnostic for quantitative evaluation of small vessel disease in patients with chronic foot ulcers, diabetes and other peripheral arterial disease. Skin perfusion pressures are not affected by edema, anemia, medial calcification or certain other conditions that limit the usefulness of other measurement technologies.

For more information about VÄSAMED technology and services, see the company's web sites at [www.vasamed.com](http://www.vasamed.com). For more information about Nellcor® *CapnoProbe*<sup>™</sup> Sublingual (SL) System, see [www.nellcor.com](http://www.nellcor.com).

###

5/17/04